The male beard hair and facial skin – challenges for shaving
| 107. | Maurer, M., Rietzler, M., Burghardt, R., and Siebenhaar, F.: The male beard hair and facial skin – challenges for shaving. Int. J. Cosmet. Sci. 2016: 38; Suppl. 1; 3-9. IF: 1.58 |
r.107
Results
Found 544 hits.
Search Results for: L3M2 Studienmaterialien: Ethical Procurement and Supply - L3M2 Torrent Prüfung - L3M2 wirkliche Prüfung 🍱 Suchen Sie auf （ www.itzert.com ） nach 《 L3M2 》 und erhalten Sie den kostenlosen Download mühelos 🙁L3M2 Prüfungs-Guide – Page 12
Skin mast cells control T cell-dependent host defense in Leishmania major infections
| 46 | Maurer, M. Lopez Kostka, S., Siebenhaar, F., Moelle, K., Metz, M., Knop, J., and von Stebut, E.+: Skin mast cells control T cell-dependent host defence in Leishmania major infections. FASEB J. 2006: 20; 2460-2467. IF: 6.72 |
Selected urticaria patients benefit from a referral to tertiary care centers – results of an expert survey
| 156 | Weller, K., Schoepke, N., Krause, K., Ardelean, E., Bräutigam, M., and Maurer, M.+: Selected urticaria patients benefit from a referral to tertiary care centers – results of an expert survey. J. Eur. Acad. Dermatol. Venereol. 2013: 27; e8-e16. IF: 2.78 |
Learnings from real-life experience of using omalizumab for chronic urticaria in Latin America
| 347 | Cherrez-Ojeda, I.+, Maurer, M., Bernstein, J. A., Vanegas, E., Felix, M., Ramon, G. D., Ensina, L. F., Larco Sousa, J. I., Matos Benavides, E. E., Cardona Villa, R., Latour Staffeld, P., Morfin-Maciel, B. M., Mori, J., Wilches, P. C.; Mata, V. L., and Cherrez, A.: Learnings from real-life experience of using omalizumab for chronic urticaria in Latin America. World Allergy Organ. J. 2019: 12; 100011. IF: TBD (IF 2018: 3.68) |
o.347
The international WAO/EAACI guideline for the management of hereditary angioedema – the 2021 revision and update
|
472. |
Maurer, M.+, Magerl, M.+*, Betschel, S.*, Aberer, W., Ansotegui, I. J., Aygören-Pürsün, E., Banerji, A., Bara, N.-A., Boccon-Gibod, I., Bork, K., Bouillet, L., Boysen, H. B., Brodszki, N., Busse, P. J., Bygum, A., Caballero, T., Cancian, M., Castaldo, A., Cohn, D. M., Csuka, D., Farkas, H., Gompels, M., Gower, R., Grumach, A. S., Guidos-Fogelbach, G., Hide, M., Kang, H.-R., Kaplan, A. P., Katelaris, C., Kiani-Alikhan, S., Lei, W.-T., Lockey, R., Longhurst, H., Lumry, W. R., MacGinnitie, A., Malbran, A., Martinez Saguer, I., Matta, J J., Nast, A., Nguyen, D., Nieto-Martinez, S. A., Pawankar, R., Peter, J., Porebski, G., Prior, N., Reshef, A., Riedl, M., Ritchie, B., Sheikh, F. R., Smith, W. B., Spaeth, P. J., Stobiecki, M., Toubi, E., Varga, L. A., Weller, K., Zanichelli, A., Zhi, Y., Zuraw, B., and Craig, T.*: The international WAO/EAACI guideline for the management of hereditary angioedema – the 2021 revision and update. Allergy 2022: 77; 1961-1990 IF: 12.40 |
o.472
The international WAO/EAACI guideline for the management of hereditary angioedema – the 2021 revision and update
|
483. |
Maurer, M.+, Magerl, M.+*, Betschel, S.*, Aberer, W., Ansotegui, I. J., Aygören-Pürsün, E., Banerji, A., Bara, N.-A., Boccon-Gibod, I., Bork, K., Bouillet, L., Boysen, H. B., Brodszki, N., Busse, P. J., Bygum, A., Caballero, T., Cancian, M., Castaldo, A., Cohn, D. M., Csuka, D., Farkas, H., Gompels, M., Gower, R., Grumach, A. S., Guidos-Fogelbach, G., Hide, M., Kang, H.-R., Kaplan, A. P., Katelaris, C., Kiani-Alikhan, S., Lei, W.-T., Lockey, R., Longhurst, H., Lumry, W. R., MacGinnitie, A., Malbran, A., Martinez Saguer, I., Matta, J J., Nast, A., Nguyen, D., Nieto-Martinez, S. A., Pawankar, R., Peter, J., Porebski, G., Prior, N., Reshef, A., Riedl, M., Ritchie, B., Sheikh, F. R., Smith, W. B., Spaeth, P. J., Stobiecki, M., Toubi, E., Varga, L. A., Weller, K., Zanichelli, A., Zhi, Y., Zuraw, B., and Craig, T.*: The international WAO/EAACI guideline for the management of hereditary angioedema – the 2021 revision and update. World Allergy Organ. J. 2022: 15; 100627. IF: 5.10 |
o.483
Efficacy and safety of treatment with omalizumab for chronic spontaneous urticaria – a systematic review for the EAACI biologicals guidelines
| 412. | Agache, I.+, Rocha, C., Pereira, A., Song, Y., Alonso-Coello, P., Solà, I., Beltran, J., Posso, M., Akdis, C., Akdis, M., Brockow, K., Chivato, T., del Giacco, S., Eiwegger, T., Eyerich, K., Giménez-Arnau, A., Gutermuth, J., Guttman-Yassky, E., Maurer, M., Ogg, G., Ong, P., O’Mahony, L., Schwarze, J., Werfel, T., Canelo-Aybar, C., Palomares, O., and Jutel, M.: Efficacy and safety of treatment with omalizumab for chronic spontaneous urticaria – a systematic review for the EAACI biologicals guidelines. Allergy 2021: 76; 59-70. IF: 14.71 |
o.412
EAACI/GA²LEN/EDF/WAO guideline: management of urticaria
| 79 | Zuberbier, T.+, Asero, R., Bindslev-Jensen, C., Canonica, G. W., Church, M. K., Giménez-Arnau, A. M., Grattan, C. E. H., Kapp, A., Maurer, M. Merk, H. F., Rogala, B., Saini, S., Sánchez-Borges, M., Schmid-Grendelmeier, P., Schünemann, H., Staubach, P., Vena, G. A., and Wedi, B.: EAACI/GA²LEN/EDF/WAO Guideline: Management of urticaria. Allergy 2009: 64; 1427-1443. IF: 6.38 |
0.079
EAACI/GA²LEN/EDF/WAO guideline: definition, classification and diagnosis of urticaria
| 80 | Zuberbier, T.+, Asero, R., Bindslev-Jensen, C., Canonica, G. W., Church, M. K., Giménez-Arnau, A. M., Grattan, C. E. H., Kapp, A., Merk, H. F., Rogala, B., Saini, S., Sánchez-Borges, M., Schmid-Grendelmeier, P., Schünemann, H., Staubach, P., Vena, G. A., Wedi, B., and Maurer, M.: EAACI/GA²LEN/EDF/WAO Guideline: Definition, classification and diagnosis of urticaria. Allergy 2009: 64; 1417-1426. |
o.080
Classification and diagnosis of urticaria: German language version of the international S3-guideline
| 112 | Zuberbier, T.+, Aberer, W., Brockow, K., Grabbe, J., Hamelmann, E., Hartmann, K., Jakob, T., Merk, H., Ollert, M., Ruëff, F., Schmid-Grendelmeier, P., Staubach, P., Voigtmann, I., Wedi, B., and Maurer, M.: Classification and diagnosis of urticaria: German language version of the international S3-guideline. Allergo J. 2011: 20; 249-258. IF: N/A |